Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Eli Lilly and Co | 31 |
| 2 | Colucid Pharmaceuticals Inc | 6 |
Where innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 65 |
| 2 | A61K | Medicinal preparations | 46 |
| 3 | C07D | Heterocyclic compounds | 41 |
| 4 | C07B | General methods of organic chemistry | 21 |
| 5 | Y02P | Climate change mitigation: production | 15 |
| 6 | C07C | Acyclic and carbocyclic compounds | 14 |
| 7 | C07K | Peptides | 10 |
| 8 | Y02E | Climate change mitigation: energy | 3 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | John H. Krege | Eli Lilly (United States) | 18 |
| 2 | Erin Doty | Eli Lilly (United States) | 10 |
| 3 | Mika Komori | Eli Lilly (Japan) | 9 |
| 4 | Li Shen Loo | Eli Lilly (United States) | 7 |
| 5 | Ellen B. Dennehy | Purdue University West Lafayette | 6 |
| 6 | Simin Baygani | Eli Lilly (United States) | 6 |
| 7 | Darren Wilbraham | Eli Lilly (United States) | 5 |
| 8 | Helen Hochstetler | Eli Lilly (United States) | 5 |
| 9 | Joel Raskin | Eli Lilly (United States) | 5 |
| 10 | Max Tsai | Eli Lilly (United States) | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine | 2019 | 277 | Migraine and Headache Studies |
| Lasmiditan is an effective acute treatment for migraine | 2018 | 269 | Migraine and Headache Studies |
| Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study | 2012 | 187 | Migraine and Headache Studies |
| Gepants for the treatment of migraine | 2019 | 159 | Migraine and Headache Studies |
| Targeted 5-HT1F Therapies for Migraine | 2018 | 122 | Migraine and Headache Studies |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Lasmiditan HCl?
Which organizations hold the most patents related to Lasmiditan HCl?
What is the primary research focus in published literature on Lasmiditan HCl?
Who are the most prolific authors publishing research on Lasmiditan HCl?
What patent classification codes are most relevant to Lasmiditan HCl technology?